Skip to main content
OpenTrials
Completed

NCT Number: NCT02870452

Effectiveness of Psychological Interventions in Haemophilia

The purpose of this study is to evaluate the relative effectiveness of two psychological interventions, cognitive-behavioral therapy (CBT) and hypnosis (Hyp), in preventing and managing pain, regulating emotional state and improving quality of life in Portuguese PWH.

Completed

Looking for future studies?

Notify Me

Key information

About this study

22 (People with Haemophilia) PWH will be included in each group (Hypnosis, CBT and control-no intervention) (total=66). Sample size was calculated using G*Power 3.1.4 and considering the following assumptions: to perform a one-way ANOVA with fixed effects, a large effect size (f =0.4), a significance level (α - type I error) of 0.05 and a statistical power (1-β - type II error) of 0.80.

The patients will be approached by clinicians of the Immunohaemotherapy Department and the psychologists for the explanation of the study, confidentiality and voluntary nature of participation. Patients who agree to participate will be asked to read and sign the Informed Consent document. Afterwards, the first assessment moment will take place in order to get a baseline assessment of each patient (T0: pre-test). Subsequently, the blind randomization to one of the 3 conditions will occur and the 4 individual intervention sessions will be scheduled, occurring in a weekly basis (90 minutes per session).

The post-test assessment (T1) takes place one week after the last intervention session (in the 5th week), and the follow-up assessments (T2, T3 and T4) will occur subsequently at 3 months, 6 months and one year post-intervention.

A physiological assessment will be performed at T1, T2 and T4. This will be performed through the collection of blood samples in order to achieve a systemic evaluation of pro-inflammatory and anti-inflammatory cytokines. A CBC (Complete Blood Count) with White Blood Count and C Reactive Protein (CRP) analysis will also be performed. Upon arrival at the Immunohaemotherapy Department (between 9:30 am and 1:30 pm), patients will undergo sample blood collection and EDTA-samples will be transported immediately to the lab.

In the lab, blood samples are centrifuged 15 minutes at 3.000 rpm, and plasma aliquoted and stored in a freezer at -80 ºC, until further analysis. Plasma levels of cytokines (IL-6, IL-1β, TNF-α, IL-10) are assayed in duplicate using ultra-sensitive multiplex human ELISA kits (Life Technologies®).

Functional Assessment of the joints will be performed through the Gilbert (based on clinical evaluation) and Pettersson Scores (based on X-ray and ultrasonography).

All study procedures will comply with the applicable ethical guidelines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mild pr severe Haemophilia A or B
  • Age of 18 or older
  • Ability to write and read

Exclusion criteria

  • Other comorbid life threatening diseases, such as cancer
  • Neurological or psychiatric deficits
  • Acquired Haemophilia

Treatment and study plan

hypnosis

Behavioral

4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.

Cognitive-Behavioral Therapy

Behavioral

4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.

Primary outcomes

  1. Pain intensity at 1 week as assessed by Numeric Rating Scale (NRS)

    Time frame: 1 week post-intervention

  2. Pain intensity at 3 months as assessed by NRS

    Time frame: 3 months post-intervention

  3. Pain intensity at 6 months as assessed by NRS

    Time frame: 6 months post-intervention

  4. Pain intensity at 12 months as assessed by NRS

    Time frame: 12 months post-intervention

Secondary outcomes

  1. Health Related Quality of Life (HRQOL) at 1 week as assessed by A36Hemofilia-Qol

    Time frame: 1 week

  2. HRQOL at 3 months as assessed by A36Hemofilia-Qol

    Time frame: 3 months

  3. HRQOL at 6 months as assessed by A36Hemofilia-Qol

    Time frame: 6 months

  4. HRQOL at 12 months as assessed by A36Hemofilia-Qol

    Time frame: 12 months

  5. Haemophilia related functional limitations at 1 week as assessed by Haemophilia Activities List (HAL)

    Time frame: 1 week

  6. Haemophilia related functional limitations at 3 months as assessed by HAL

    Time frame: 3 months

  7. Haemophilia related functional limitations at 6 months as assessed by HAL

    Time frame: 6 months

  8. Haemophilia related functional limitations at 12 months as assessed by HAL

    Time frame: 12 months

  9. Anxiety at 1 week as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS)-Anxiety Short Form v1.0

    Time frame: 1 week

  10. Anxiety at 3 months as assessed by PROMIS-Anxiety Short Form v1.0

    Time frame: 3 months

  11. Anxiety at 6 months as assessed by PROMIS-Anxiety Short Form v1.0

    Time frame: 6 months

  12. Anxiety at 12 months as assessed by PROMIS-Anxiety Short Form v1.0

    Time frame: 12 months

  13. Depression at 1 week as assessed by PROMIS-Depression Short Form v1.0

    Time frame: 1 week

  14. Depression at 3 months as assessed by PROMIS-Depression Short Form v1.0

    Time frame: 3 months

  15. Depression at 6 months as assessed by PROMIS-Depression Short Form v1.0

    Time frame: 6 months

  16. Depression at 12 months as assessed by PROMIS-Depression Short Form v1.0

    Time frame: 12 months

  17. Pain Catastrophizing at 1 week as assessed by Coping Strategies Questionnaire (CSQ) Catastrophizing Subscale

    Time frame: 1 week

  18. Pain Catastrophizing at 3 months as assessed by CSQ Catastrophizing Subscale

    Time frame: 3 months

  19. Pain Catastrophizing at 6 months as assessed by CSQ Catastrophizing Subscale

    Time frame: 6 months

  20. Pain Catastrophizing at 12 months as assessed by CSQ Catastrophizing Subscale

    Time frame: 12 months

  21. Illness Perception (Personal Control) at 1 week as assessed by Revised Illness Perception Questionnaire (IPQ-R)

    Time frame: 1 week

  22. Illness Perception (Emotional Representation) at 1 week as assessed by IPQ-R

    Time frame: 1 week

  23. Illness Perception (Personal Control) at 3 months as assessed by IPQ-R

    Time frame: 3 months

  24. Illness Perception (Emotional Representation) at 3 months as assessed by IPQ-R

    Time frame: 3 months

  25. Illness Perception (Personal Control) at 6 months as assessed by IPQ-R

    Time frame: 6 months

  26. Illness Perception (Emotional Representation) at 6 months as assessed by IPQ-R

    Time frame: 6 months

  27. Illness Perception (Personal Control) at 12 months as assessed by IPQ-R

    Time frame: 12 months

  28. Illness Perception (Emotional Representation) at 12 months as assessed by IPQ-R

    Time frame: 12 months

  29. Number of joint bleeds in the previous month, at 1 week

    Time frame: 1 week

  30. Number of joint bleeds in the previous month, at 3 months

    Time frame: 3 months

  31. Number of joint bleeds in the previous month, at 6 months

    Time frame: 6 months

  32. Number of joint bleeds in the previous month, at 12 months

    Time frame: 12 months

  33. Analgesic intake in the previous month, at 1 week

    Time frame: 1 week

  34. Analgesic intake in the previous month, at 3 months

    Time frame: 3 months

  35. Analgesic intake in the previous month, at 6 months

    Time frame: 6 months

  36. Analgesic intake in the previous month, at 12 months

    Time frame: 12 months

  37. Replacement factor (VIII/IX) consumption in the previous month, at 1week

    Time frame: 1 week

  38. Replacement factor (VIII/IX) consumption in the previous month, at 3 months

    Time frame: 3 months

  39. Replacement factor (VIII/IX) consumption in the previous month, at 6 months

    Time frame: 6 months

  40. Replacement factor (VIII/IX) consumption in the previous month, at 12 months

    Time frame: 12 months

  41. Pettersson Score at 3 months

    Time frame: 3 months

    Radiologic classification of PWH joint status

  42. Pettersson Score at 12 months

    Time frame: 12 months

    Radiologic classification of PWH joint status

  43. Gilbert Score at 3 months

    Time frame: 3 months

    Joint health evaluation, in the domain of body structure and function (i.e. impairment), of the joints most commonly affected by bleeding in hemophilia - knees, ankles, elbows

  44. Gilbert Score at 12 months

    Time frame: 12 months

    Joint health evaluation, in the domain of body structure and function (i.e. impairment), of the joints most commonly affected by bleeding in hemophilia - knees, ankles, elbows

  45. IL-6 Cytokine at 3 months

    Time frame: 3 months

  46. IL-6 Cytokine at 12 months

    Time frame: 12 months

  47. IL-1β Cytokine at 6 months

    Time frame: 6 months

  48. IL-1β Cytokine at 12 months

    Time frame: 12 months

  49. IL-10 Cytokine at 6 months

    Time frame: 6 months

  50. IL-10 Cytokine at 12 months

    Time frame: 12 months

  51. TNF-α Cytokine at 6 months

    Time frame: 6 months

  52. TNF-α Cytokine at 12 months

    Time frame: 12 months

  53. C Reactive Protein at 6 months

    Time frame: 6 months

  54. C Reactive Protein at 12 months

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

University of Minho

Other

Collaborators

  • Hospital Sao Joao

Registry information

Official study title

Effectiveness of Two Psychological Interventions for Prevention and Management of Pain, Emotional Regulation and Promotion of Quality of Life in People With Haemophilia: a Randomized Controlled Trial

Acronym: PSY_HaEMOPEQ

Important dates

Study start
2018
Primary completion
2018
Study completion
2018
First posted
Aug 17, 2016
Registry last updated
Mar 26, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.